The Second PR was very sloppily written, ambiguous

The Second PR was very sloppily written, ambiguous, unclear. I could have done a much better job. But my point is, my observation is, that I think Dr Nader P., yes is enthusiastic and optimistic, yet also very deeply committed, expecting wealth, and in "CONTROL" of everything, but not actually worthy of the control he has. Last night with Dr Been, Nader was ....can't think of an adjective, but I think Dr Been was bewildered or shocked to put it mildly. Why does Nader do all the interviews (control), Imagine if Nader had not done the Dr Been interview yesterday, seriously, I think our share price may have gone into orbit tomorrow. Now, in IMO, it will be mildly green or deeply red. Don't know, The 2 PRs may bring in new investors. There is virtually no descent treatment for severe nor critical nor for dying cv19 patients, and leronlimab is at a minimun, a strong drug for these folks. No announced EUA is sad, maybe pathetic.

Janet Woodcock really should have already announced an EUA adding that further data is needed for a full approval. (eINDs old & new, both trials, OLE) Hey, LL is pretty safe, like...extremely safe. No EUA, no discussion of potential for a rapid EUA is interesting and concerning. I am concerned about the FDA, not concerned for LL potential,

"Slow shorts" and "subtle shorts" are everywhere and longs generally have agendas and/or are emotional involved and/or are attached, protecting their investment, for some, their large investments.

"Convincing" longs are generally ok and confident regarding the long term prospects for Cytodyn and Leronlimab.